TrialClinical and experimental immunology2015

Oral administration of non-absorbable delayed release 6-mercaptopurine is locally active in the gut, exerts a systemic immune effect and alleviates Crohn's disease with low rate of side effects: results of double blind Phase II clinical trial.

E Israeli et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.